RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5551
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation ; day:13 ; month:2 ; year:2019 ; pages:1-16
Leukemia ; (13.2.2019), 1-16
- Urheber
-
Zhou, Nan
Gutierrez-Uzquiza, Alvaro
Zheng, Xiang Yu
Chang, Renxu
Vogl, Dan T.
Garfall, Alfred L.
Bernabei, Luca
Saraf, Anita
Florens, Laurence
Washburn, Michael P.
Illendula, Anuradha
Bushweller, John H.
Busino, Luca
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-019-0403-2
- URN
-
urn:nbn:de:101:1-2019031600091944705398
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhou, Nan
- Gutierrez-Uzquiza, Alvaro
- Zheng, Xiang Yu
- Chang, Renxu
- Vogl, Dan T.
- Garfall, Alfred L.
- Bernabei, Luca
- Saraf, Anita
- Florens, Laurence
- Washburn, Michael P.
- Illendula, Anuradha
- Bushweller, John H.
- Busino, Luca
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma